Enochian Biosciences, Inc. (ENOB)
Stock Price:
$3.92 USD
0.16 (4.26%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $3.93 +0.01 (0.26%) Jul 10, 5:39 PM
Key Info
| Market Cap |
182.27M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-334,047 |
| Shares Out |
46.50M |
| EPS (ttm) |
-0.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$3.92 |
| Previous Close |
$3.76 |
| Change ($) |
0.16 |
| Change (%) |
4.26% |
| Day's Open |
3.82 |
| Day's Range |
3.82 - 3.99 |
| Day's Volume |
55,910 |
| 52-Week Range |
1.95 - 13.43 |
More Stats
| Market Cap |
182.27M |
| Enterprise Value |
178.90M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.50M |
| Float |
3.66M |
| EPS (basic) |
0.03 |
| EPS (diluted) |
-0.14 |
| FCF / Share |
-0.23 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.38M |
| Short Ratio |
1.11 |
| Short % of Float |
9.71% |
| Beta |
0.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.10 |
| Revenue |
n/a |
| Operating Income |
-5.39M |
| Net Income |
-334,047 |
| Free Cash Flow |
-10.60M |
| Net Cash |
3.37M |
| Net Cash / Share |
0.07 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-4.00% |
| ROE |
-3.91% |
| ROIC |
-7.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -10.99 | -5.33 | -2.40 |
| Net Income | -18.02 | -6.31 | -2.14 |
| Shares Outstanding | 37.55 | 21.94 | 12.27 |
| Earnings Per Share | -0.48 | -0.29 | -0.17 |
| Operating Cash Flow | -8.51 | -4.34 | -1.18 |
| Capital Expenditures | -0.72 | -0.03 | - |
| Free Cash Flow | -9.22 | -4.37 | -1.18 |
| Cash & Equivalents | 12.28 | 15.60 | 3.94 |
| Total Debt | - | - | 2.09 |
| Net Cash / Debt | 12.28 | 15.60 | 1.85 |
| Assets | 180 | 183 | 4.52 |
| Liabilities | 6.78 | 23.76 | 2.99 |
| Book Value | 173 | 159 | 1.53 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Enochian Biosciences, Inc. |
| Country |
United States |
| Employees |
8 |
Stock Information
| Ticker Symbol |
ENOB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ENOB |
Description
Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.